QuantAbundanceAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

35,144 signal articles · 107 in last 24h · 178,660 total before filter · latest 1h ago

107last 24h

3126last 7d

511● bullish (7d)

311● bearish (7d)

227publishers

All Macro103 Earnings1820 M&A172 Regulatory23 Product26 Analyst28

✕ clear all filtersticker: JNJSentiment:bullish neutral bearish show all (incl. clickbait)

MarketBeat7h agoneutral

Smith & Nephew SNATS Q3 Earnings Call Highlights

PR Newswire11h agobearish

Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer

PR Newswire1d agoneutral

Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients

Motley Fool2d agobearish

4 Stocks I'm Not Selling Even If the Fed Keeps Raising Rates

Zacks2d agobullish

Halozyme Stock Down Despite Q3 Earnings and Revenue Beat

MT Newswires2d agoneutral

Halozyme Says US FDA Approves Rybrevant Faspro Co-Formulated With Enhanze to Treat Head, Neck Cancer

PR Newswire2d agoneutral

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer

The Wall Street Journal2d agobearish

Healthcare Stocks Fall as Market Rout Spreads

ABBV JNJ LLY MRK ^GSPC

Investing.com3d agobullish

Johnson & Johnson wins FDA approval for Rybrevant cancer treatment

PR Newswire3d agoneutral

Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer

24/7 Wall St.3d agoneutral

Rate Hikes Could Be Coming: History Likes These 4 Dividend Stocks

TIKR4d agobullish

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zacks4d agoneutral

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates

MT Newswires4d agobearish

Update: Smith & Nephew Confirms Merger Talks With J&J's Orthopedics Unit Have Ended, Cuts 2026 Revenue Outlook

MT Newswires4d agoneutral

Smith & Nephew Confirms Merger Talks With J&J's Orthopedics Unit Have Ended

24/7 Wall St.5d agoneutral

AbbVie Hit a New High After Earnings. There’s More Upside Left.

Motley Fool5d agoneutral

Kimberly-Clark Acquires Kenvue. Here’s What Investors Need to Know Ahead of Its Nov. 5 Earnings Report.

Trefis39d agoneutral

Was The Run In JNJ Stock Hiding In Plain Sight?

ABBV JNJ LLY MRK PFE SPGI

GuruFocus.com40d agoneutral

BofA Raises J&J Target but Sees Q3 Earnings 12% Below Street

24/7 Wall St.41d agoneutral

Johnson & Johnson’s Next Growth Engine Is Taking Shape

24/7 Wall St.44d agoneutral

The 1 Number That Decides Whether a Dividend Lasts Your Whole Retirement

The Wall Street Journal44d agoneutral

The Peptide Boom That Isn’t About Your Muscles

24/7 Wall St.45d agoneutral

CDs Offer Certainty. Dividend Stocks Offer Something Retirees May Need More

The Wall Street Journal46d agoneutral

AI Biotech Enveda Doubles in Value to $2 Billion

Zacks47d agoneutral

JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study

Simply Wall St.47d agoneutral

What Johnson & Johnson (JNJ)'s Bipolar I Mania Data for CAPLYTA Means For Shareholders

Trefis47d agobullish

Why Is JNJ Stock Beating Rivals That Grow Faster?

ABBV JNJ LLY MRK PFE

Clinical Trials Arena47d agobullish

J&J’s Intra-Cellular buy continues to bear fruit with Caplyta bipolar win

Trefis53d agoneutral

Should You Judge JNJ Stock Without STELARA?

ABBV JNJ LLY MRK PFE

24/7 Wall St.54d agoneutral

3 Dividend Stocks Baby Boomers Should Own for the Rest of Their Lives